Latest COVID-19 News
A Message from the ACR
On behalf of its more than 7,700 members of the professional rheumatology community, the ACR wishes to express strong support for Dr. Anthony Fauci and his continued and close involvement in the work to address the nation’s response to the COVID-19 pandemic.
ACR Message in Support of Dr. Fauci
ACR Convergence 2020: COVID-19 Sessions
ACR leaders and experts in rheumatology, including Anthony Fauci, MD, shared timely insights about the impact of COVID-19 during ACR Convergence, the ACR’s annual meeting. If you missed the live virtual meeting, you can purchase the On-Demand All-Access Pass for 24/7 access to 200+ educational sessions and oral abstracts, including the COVID-19 specific sessions. On-demand access is available until March 21, 2021.
ACR Convergence 2020 On-Demand All-Access Pass Details
COVID-19 Mental Health and Well-Being Resources
Rheumatologists, healthcare professionals, and patients with rheumatic disease may feel the stress of COVID-19 even more acutely than others. See a curated collection of non-ACR resources suggested by members of the Association of Rheumatology Professionals to promote well-being, manage daily stress, and offer support during these challenging times.
COVID-19 Mental Health and Well-Being Resources
See All Breaking COVID-19 News
Practice and Advocacy Resources
The ACR’s COVID-19 Practice and Advocacy Task Force continues to work rapidly to provide support to you during this unprecedented time. You’ll find guidance documents that include approaches to drug shortages, support for telehealth, information about federal stimulus relief aid, and guidance for infusions. Working with experts in COVID-related topics, we are focused on developing meaningful information and resources to help guide you.
Practice and Advocacy Resources
COVID-19 Manufacturer Resources and Patient Assistance Programs
Clinical Guidance for Pediatric Patients
The ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic, including for the care of children with pediatric rheumatic disease, and for the management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance for Pediatric Patients
Clinical Guidance for Adult Patients with Rheumatic Diseases
The ACR has developed clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic. Populations considered include patients with a documented COVID-19 infection, those who are stable following exposure to SARS-CoV-2 (but without known infection), and patients who are stable with no infection or exposure. The recommendations address various treatment options and provide general guidance, as well as direction for when to start, stop, or reduce medications. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance for Adult Patients with Rheumatic Diseases
Questions and Feedback
Are you experiencing COVID-19 related drug shortages, practice issues, or any other problems? Share your comments and questions with us at COVID@rheumatology.org
Thank you to the corporate supporters of the ACR COVID-19 Emergency Response.
Updated December 2, 2020 at 1:30 PM ET